|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||11.41 / 24.88|
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.
NKTR-181 shows significantly less abuse potential compared to oxycodone
Huge profits could be on the doorstep for these hot breakout setups.
New NKTR-214 Data to be Highlighted at ASCO in Poster Presentation and at Investor Event
The Oracle of Omaha believes in the future of U.S. business, says Jim Cramer. Plus, Buffett can admit his mistakes and we can learn from that.
Investors in Nektar Therapeutics saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 16th contracts and identified one put and one call contract of particular interest.
Five Data Presentations Showcased Nektar's Immuno-Oncology Candidates, NKTR-214 and NKTR-255
Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
NKTR-358 is designed to correct the underlying immune system dysfunction common to many auto-immune diseases
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Here's how to trade six of the most active names on the market this afternoon.
Biotech companies show more energy than the rest of the market Monday.
CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.
Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain